Allogene Therapeutics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c
August 9, 2022 4:15 PM EDTAllogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.52), $0.09 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $8.33 thousand.
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
... More